Summary of COVID-19 amubarvimab studies

1. Evering et al., Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial

780 patient amubarvimab early treatment RCT: 91% lower mortality (p=0.006), 20% higher PASC (p=0.39), 61% lower hospitalization (p=0.0008), and 67% lower combined mortality/hospitalization (p<0.0001).
RCT 780 high-risk non-hospitalized COVID-19 patients showing significantly lower risk of hospitalization or death through 36 weeks, but no significant difference in long COVID with amubarvimab/romlusevimab treatment compared to placebo.
Aug 2024, eClinicalMedicine, https://www.sciencedirect.com/science/article/pii/S2589537024003663, https://c19p.org/evering2

2. Qu et al., Effect of amubarvimab-romlusevimab for treatment of severe COVID-19 in intensive care units: A retrospective cohort study

121 patient amubarvimab ICU PSM study: 46% lower mortality (p=0.06) and 4% improved viral clearance (p=0.89).
Retrospective 121 severe ICU COVID-19 patients in China showing lower 28-day mortality and ICU mortality with amubarvimab-romlusevimab treatment compared to no antiviral treatment. No significant differences were found in viral conversion rate or thromboembolic events. After propensity score matching to balance baseline characteristics, the mortality differences were no longer statistically significant.
Sep 2024, Heliyon, https://www.sciencedirect.com/science/article/pii/S2405844024136948, https://c19p.org/qu2

3. Yalan et al., Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study

340 patient amubarvimab late treatment study: 71% higher mortality (p=0.35), 8% higher ICU admission (p=0.8), 8% shorter hospitalization (p=0.004), and 7% faster viral clearance (p=0.004).
Retrospective 340 COVID-19 patients in China showing shorter length of hospital stay and faster viral clearance with BRII-196 plus BRII-198 monoclonal antibody treatment, especially when given early. The treatment did not show efficacy for improving clinical outcomes among severe or critical cases.
Apr 2024, BMC Pharmacology and Toxicology, https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-024-00753-7, https://c19p.org/yalan

4. Self et al., Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

354 patient amubarvimab late treatment RCT: 15% higher mortality (p=0.72) and 7% improved recovery (p=0.48).
RCT with 182 sotrovimab patients, 176 BRII-196+BRII-198 patients, and 178 control patients, median 8 days from symptom onset, showing no significant differences and terminated early due to futility.
Dec 2021, The Lancet Infectious Diseases, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00751-9/fulltext, https://c19p.org/self3am

Submit Corrections or Updates

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0